Send me real-time posts from this site at my email
Motley Fool

High Drug Prices Remains a Top Issue in Democratic Debates

One of the top issues discussed at Tuesday's Democratic debate in Iowa was healthcare. Specifically, how to lower drug prices which have been ballooning over the past few years.

Sen. Elizabeth Warren has promised to use executive action to make it easier for generic drug manufacturers to compete with branded drugs, especially if they received funding from federal sources. She went on to mention Insulin specifically, AIDS/HIV drugs, as well as EpiPens (epinephrine autoinjectors).

Image source: Getty Images.

While drug costs have always been a major issue for Democrats, healthcare questions in previous debates have revolved more around improving Medicare access. Sen. Bernie Sanders, has also made comments regarding the nature of major pharmaceutical companies, singling out firms that charge more in the U.S. than in other nations.

Why are drug costs so high?

With healthcare issues remaining a popular subject among voters, even Republicans have taken steps to combat this issue. A recent press release issued by the Trump administration mentions a plan to import prescription drugs from Canada, which are cheaper than in the U.S.

Earlier in 2019, CEOs of major drugmakers were invited to testify before a Senate Committee on the topic of drug prices. This included the chief executives from AbbVie, AstraZeneca, and six other top pharmaceutical companies. When asked why drugs cost so much in the U.S., the response from drugmakers is that America carries most of the R&D costs for the rest of the world. The idea is that without paying these higher prices, investment in new treatments would dry up.

Regardless, Democrats seem to broadly agree with changing how intellectual property works for big pharmaceuticals to allow greater competition from generic drugmakers.

10 stocks we like better than AstraZeneca
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and AstraZeneca wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

*Stock Advisor returns as of December 1, 2019

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.


Popular posts

Welcome!!! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue